Literature DB >> 11585510

Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases.

J P Triboulet1, C Mariette, D Chevalier, H Amrouni.   

Abstract

BACKGROUND: Free jejunal transfer has become the standard technique for reconstruction of the pharynx and hypopharynx, especially with proximal neoplastic lesions, whereas gastric tube interposition is the technique of choice for reconstruction of the hypopharynx and cervical esophagus when resection extends below the thoracic inlet. HYPOTHESIS: Surgical ablation is a viable option for advanced hypopharyngeal and cervical esophageal neoplasms, with stomach interposition a safe and preferred method of reconstruction.
DESIGN: Retrospective analysis.
SETTING: University hospital that is a regional referral institution for esophageal cancer treatment and complex digestive reconstructions after esophagectomy. PATIENTS: We reviewed the records of 209 patients who underwent total pharyngolaryngectomy between May 1982 and July 1999. The majority of patients had advanced cancer: hypopharyngeal in 131 cases and cervical esophageal in 78 cases.
INTERVENTIONS: Pharyngolaryngectomy and total esophagectomy with pharyngogastric anastomoses (n = 127); pharyngolaryngectomy, cervical esophagectomy, and reconstruction with free jejunal transplant (n = 77); and pharyngolaryngectomy and total esophagectomy with pharyngocolic anastomoses (n = 5). MAIN OUTCOME MEASURES: Postoperative mortality and morbidity, long-term survival, and prognostic factors influencing survival.
RESULTS: The postoperative in-hospital mortality rate was 4.8% (10 patients), with a postoperative morbidity rate of 38.3%. Alimentary continuity was achieved using the stomach (127 patients), colon (5 patients), or free jejunal autograft (77 patients). The 1-year and 5-year survival rates were 62% and 24%, respectively. There was no significant difference with regard to the survival between gastric transposition and free jejunal autograft, but there were fewer complications in the gastric pull-up group (33% vs 47%, P<.05). The significant adverse factors affecting survival were tumor cervical localization, postoperative complications, disease stages pT3 and pT4 for the cervical esophageal tumors, microscopic pharyngeal penetration, or incomplete resection. The significant beneficial factors were tumor hypopharyngeal localization and postoperative radiotherapy.
CONCLUSIONS: Surgical ablation is a viable option for advanced hypopharyngeal and cervical esophageal neoplasms, with stomach interposition the preferred method of reconstruction. Although the prognosis is poor, satisfactory short-term palliation can be achieved. The significant adverse factors affecting survival should be taken into account to select the candidates for surgery.

Entities:  

Mesh:

Year:  2001        PMID: 11585510     DOI: 10.1001/archsurg.136.10.1164

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  44 in total

1.  Functional and radiological evaluation of free jejunal transplant reconstructions after radical resection of hypopharyngeal or proximal esophageal cancer.

Authors:  H Bergquist; M Andersson; H Ejnell; M Hellström; L Lundell; M Ruth
Journal:  World J Surg       Date:  2007-10       Impact factor: 3.352

Review 2.  Free jejunal graft reconstruction after resection of neck cancers: our surgical technique.

Authors:  Masahide Ikeguchi; Takanori Miyake; Tomoyuki Matsunaga; Manabu Yamamoto; Youji Fukumoto; Yosinori Yamada; Kenji Fukuda; Hiroaki Saito; Shigeru Tatebe; Shun-ichi Tsujitani
Journal:  Surg Today       Date:  2009-11-01       Impact factor: 2.549

3.  Hypopharyngeal reconstruction: a comparison of three alternatives.

Authors:  Alaa Eldin Elfeky; Wail Fayez Nasr; Alaa Khazbak; Mohamed Said Abdelrahman; Zaki Abdelgawad Allam; Wahed Yousry Gareer; Hesham Elsebaey
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-09-27       Impact factor: 2.503

4.  Larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction: A promising treatment for selected cervical esophageal squamous cell carcinoma.

Authors:  Wu-Ping Wang; Jie Ma; Qiang Lu; Yong Han; Xiao-Fei Li; Tao Jiang; Jin-Bo Zhao
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

5.  Identification of potential plasma biomarkers for esophageal squamous cell carcinoma by a proteomic method.

Authors:  Jia Zhao; Yu-Xia Fan; Yang Yang; Dong-Lei Liu; Kai Wu; Feng-Biao Wen; Chun-Yang Zhang; Deng-Yan Zhu; Song Zhao
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

6.  Efficacy of Staged Treatment Strategy for Patients with Synchronous Double Cancers of the Esophagus and Head and Neck: A Retrospective Study.

Authors:  Akira Matsumoto; Masayuki Watanabe; Hironobu Shigaki; Koujiro Nishida; Shinji Mine; Takeshi Sano; Katsuhiko Yanaga
Journal:  World J Surg       Date:  2016-02       Impact factor: 3.352

7.  Feasibility, efficacy and safety of stent insertion as a palliative treatment for malignant strictures in the cervical segment of the esophagus and the hypopharynx.

Authors:  Giorgio Battaglia; Alessandro Antonello; Stefano Realdon; Francesco Cavallin; Francesca Giacomini; Sauid Ishaq
Journal:  Surg Endosc       Date:  2015-04-01       Impact factor: 4.584

8.  Micrometastasis of hypopharyngeal cancer.

Authors:  P Sabljak; P Pesko; D Stojakov; M Micev; E Keramatollah; D Velickovic; O Skrobic; V Sljukic; A Djikic-Rom
Journal:  Langenbecks Arch Surg       Date:  2014-05-11       Impact factor: 3.445

9.  Larynx-preserving limited resection and free jejunal graft for carcinoma of the cervical esophagus.

Authors:  Hiroshi Miyata; Makoto Yamasaki; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

10.  Early and long-term morbidity after total laryngopharyngectomy.

Authors:  Stijn Keereweer; Johannes H W de Wilt; Aniel Sewnaik; Cees A Meeuwis; Hugo W Tilanus; Jeroen D F Kerrebijn
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-04-07       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.